Two major reasons compel us to study tumour heterogeneity: firstly, it represents the basis of acquired therapy resistance, and secondly it may be one of the major sources of the low level of reproducibility in clinical cancer research. The present review focuses on the heterogeneity of neoplastic disease, both within the primary tumour, and between primary tumour and metastases. We discuss different levels of heterogeneity and the current understanding of the phenomenon, as well as imminent developments relevant for clinical research and diagnostic pathology. It is necessary to develop new tools to study heterogeneity and new biomarkers for heterogeneity. Established and new in situ methods will be very useful. In future studies, not only clonal heterogeneity needs to be addressed, but also non-clonal phenotypic heterogeneity which might be important for therapy resistance. We also review heterogeneity established in major tumour types, in order to explore potential similarities that might help to define new strategies for targeted therapy.

Tumour heterogeneity: principles and practical consequences

STANTA, GIORGIO;BONIN, Serena;
2016-01-01

Abstract

Two major reasons compel us to study tumour heterogeneity: firstly, it represents the basis of acquired therapy resistance, and secondly it may be one of the major sources of the low level of reproducibility in clinical cancer research. The present review focuses on the heterogeneity of neoplastic disease, both within the primary tumour, and between primary tumour and metastases. We discuss different levels of heterogeneity and the current understanding of the phenomenon, as well as imminent developments relevant for clinical research and diagnostic pathology. It is necessary to develop new tools to study heterogeneity and new biomarkers for heterogeneity. Established and new in situ methods will be very useful. In future studies, not only clonal heterogeneity needs to be addressed, but also non-clonal phenotypic heterogeneity which might be important for therapy resistance. We also review heterogeneity established in major tumour types, in order to explore potential similarities that might help to define new strategies for targeted therapy.
2016
Pubblicato
http://link.springer.com/article/10.1007%2Fs00428-016-1987-9
File in questo prodotto:
File Dimensione Formato  
art%3A10.1007%2Fs00428-016-1987-9.pdf

Accesso chiuso

Tipologia: Documento in Versione Editoriale
Licenza: Digital Rights Management non definito
Dimensione 605.99 kB
Formato Adobe PDF
605.99 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
2886039_art_10.1007_s00428-016-1987-9-PostPrint.pdf

Open Access dal 14/07/2017

Descrizione: Post Print VQR3 - This is a post-peer-review, pre-copyedit version of an article published in Virchows Archiv. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00428-016-1987-9.
Tipologia: Bozza finale post-referaggio (post-print)
Licenza: Digital Rights Management non definito
Dimensione 998.85 kB
Formato Adobe PDF
998.85 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2886039
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 26
social impact